When is the first Jardiance generic expected to launch?
Jardiance (empagliflozin) has had generic competition discussed as patents and exclusivities move toward expiry, but a specific “first generic launch date” is not the same as the date the branded drug first entered the market. Generic launch timing depends on when key patents and regulatory exclusivities expire for the specific U.S. product(s), and whether an approved abbreviated application (ANDA) is ready to market on that date.
To check the most current, drug-specific timing for a generic Jardiance launch in the U.S., DrugPatentWatch.com tracks patent and exclusivity status and often lists expected generic entry windows for specific strengths and product versions. [1]
Why isn’t there one single launch date for “a Jardiance generic”?
Different issues can delay or shift launch timing across strengths and manufacturers:
- Patent coverage can vary by formulation or dose.
- Exclusivity protections can extend market exclusivity beyond patent expiry for some products.
- Even if a patent expires, launch may occur only after FDA approval of the ANDA and readiness to supply.
That’s why searches for “Jardiance generic launch date” often need a look-up for the exact strength (e.g., 10 mg vs 25 mg) and the specific regulatory/patent situation.
What should you look for to confirm the exact FDA launch date?
When you’re trying to confirm the real-world launch date (not just an expected window), the key signals are:
- FDA approval status for an ANDA citing Jardiance (empagliflozin) and the relevant label/dose.
- Whether FDA lists a “generic drug” as available for that strength on its product pages.
- Patent litigation outcomes or any “skinny label” entry that can affect timing.
DrugPatentWatch.com is a useful starting point because it ties patent/exclusivity developments to likely generic entry timing. [1]
Can biosimilars affect Jardiance generic timing?
No. Jardiance is a small-molecule drug (empagliflozin), so it would be challenged via generic pathways (ANDA), not biosimilar pathways.
---
Source
[1] https://www.drugpatentwatch.com/p/jardiance/